Search

Aim: This study aimed to investigate the relationships among factors affecting compassion fatigue/secondary traumatic stress, burnout, and compassion satisfaction in Japanese nurses, focusing on self‐compassion, fears of compassion, and attachment styles. Methods: This cross‐sectional observational study enrolled 400 clinical nurses (aged ≥20 years) in Japan, registered with an online survey company, from June 6 to June 26, 2021. The subjects completed a web‐based questionnaire that assessed compassion fatigue/secondary traumatic stress, burnout, compassion satisfaction, self‐compassion, fears of compassion for self, anxiety, and avoidance. Additionally, descriptive statistics, correlation analysis, multiple regression analysis and path analysis were performed to examine the relationships among the influencing factors. Results: Compassion fatigue/secondary traumatic stress was influenced by anxiety and fears of compassion for self (R2 =.31). Burnout was affected by compassion fatigue/secondary traumatic stress, compassion satisfaction, self‐compassion, anxiety, and avoidance (R2 =.63). Compassion satisfaction was impacted by self‐compassion, anxiety, and fears of compassion for self (R2 =.31). Additionally, self‐compassion (R2 =.28) and fears of compassion for self (R2 =.55) were influenced by anxiety and avoidance. Conclusions: Compassion fatigue/secondary traumatic stress leads to burnout, whereas compassion satisfaction moderates burnout. Furthermore, there were associations among the factors leading to compassion fatigue/secondary traumatic stress and burnout and compassion satisfaction. Therefore, an approach that enhances self‐compassion and promotes the development of a stable attachment style could mitigate compassion fatigue/secondary traumatic stress and fears of compassion for self while moderately maintaining and improving compassion satisfaction. [ABSTRACT FROM AUTHOR]

Abstract: Aim: Primary malignant lymphomas arising from the female genital tract are very rare, with an incidence rate of 0.5%. Because of its rarity, its clinical characteristics, prognosis and optimal treatment are still unclear. Here, we retrospectively evaluated female patients with uterine lymphoma. Methods: Between January 2000 and October 2016, 4362 patients were newly diagnosed with malignant lymphoma by the participating institutions of YACHT. Among these 4362 patients, we retrospectively evaluated 14 adult patients with primary uterine lymphoma. Results: The median follow up time was 41 months. The median age at diagnosis was 68 years. Of 14 patients, 10 (72%) were diagnosed with diffuse large B‐cell lymphoma. Seven patients presented with vaginal bleeding and three with abdominal pain. Eleven patients (79%) had advanced stages at diagnosis. Three patients (21%) had ovarian involvement and 2 (14%) had vaginal involvement. Induction chemotherapy regimens were R‐CHOP in seven patients (50%), CHOP in three (21%) and other regimens in four (29%). Among 14 patients, 12 patients (86%) achieved a complete response and 2 (14%) experienced disease progression. Three patients (21%) showed relapse. Five patients (36%) died because of malignant lymphoma. The 3‐year overall survival rate was 57.9%. Soluble interleukin‐2 receptor levels > 5000 U/mL, anemia, a bulky mass and the presence of > 1 extranodal sites, B symptom at diagnosis were associated with a poor prognosis. Conclusion: Female genital lymphoma is very rare, and further study of more cases is warranted. [ABSTRACT FROM AUTHOR]

The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in patients with chronic myeloid leukemia ( CML). Recently, a new European Treatment and Outcome Study ( EUTOS) scoring system was developed. We performed a multicenter retrospective study to validate the effectiveness of each of the three scoring systems. The study cohort included 145 patients diagnosed with CML in chronic phase who were treated with imatinib. In the EUTOS low- and high-risk groups, the cumulative incidence of complete cytogenetic response ( CCyR) at 18 months was 86.9% and 87.5% ( P = 0.797) and the 5-year overall survival rate was 92.6% and 93.3% ( P = 0.871), respectively. The cumulative incidence of CCyR at 12 months, 5-year event-free survival and 5-year progression-free survival were not predicted using the EUTOS scoring system. However, there were significant differences in both the Sokal score and Hasford score risk groups. In our retrospective validation study, the EUTOS score did not predict the prognosis of patients with CML in chronic phase treated with imatinib. [ABSTRACT FROM AUTHOR]

Long-term observation has identified a pattern of continuing relapse in limited stage diffuse large B-cell lymphoma ( DLBCL) treated by three cycles of R- CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus involved-field irradiation. We retrospectively analysed 190 untreated patients with limited stage DLBCL treated by R- CHOP alone. All the patients were scheduled to undergo primary therapy with six cycles of full-dose R- CHOP. Cases with a dose reduction of more than 20% were excluded from the study. Additional local irradiation was allowed in patients with partial response ( PR). Five patients received additional local irradiation after PR at the end of the R- CHOP therapy. The median observation period was 52 months. Median age at diagnosis was 63 years. The responses to therapy were 180 complete responses, eight PR, and two progression of disease ( PD). The 5-year progression-free survival and 5-year overall survival rates were 84% and 90%, respectively, both in plateau. During the observation period, 29 patients experienced PD. The progression sites were the primary sites in 15 patients, outside the primary sites in 10, and undetermined in four patients. These results suggest that the 'standard' strategy of three cycles of R- CHOP followed by involved-field radiotherapy for limited stage DLBCL could be effectively replaced by six cycles of R- CHOP alone. [ABSTRACT FROM AUTHOR]